CY1121606T1 - Σκευασματα συνδυασμου νεοσαξιτοξινης για παρατεταμενη τοπικη αναισθησια - Google Patents

Σκευασματα συνδυασμου νεοσαξιτοξινης για παρατεταμενη τοπικη αναισθησια

Info

Publication number
CY1121606T1
CY1121606T1 CY20191100416T CY191100416T CY1121606T1 CY 1121606 T1 CY1121606 T1 CY 1121606T1 CY 20191100416 T CY20191100416 T CY 20191100416T CY 191100416 T CY191100416 T CY 191100416T CY 1121606 T1 CY1121606 T1 CY 1121606T1
Authority
CY
Cyprus
Prior art keywords
neostx
bupivacaine
combination
epinephrine
local anesthesia
Prior art date
Application number
CY20191100416T
Other languages
English (en)
Inventor
Charles Berde
Daniel S. Kohane
Original Assignee
The Children's Medical Center Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549480&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121606(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Children's Medical Center Corporation filed Critical The Children's Medical Center Corporation
Publication of CY1121606T1 publication Critical patent/CY1121606T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Καθώς καθένας από τους αναστολείς διαύλου νατρίου θέσης I έχει μια μοναδική δράση και δεν μπορεί να χρησιμοποιηθεί για να συναχθεί η ίδια αποτελεσματική δοσολογία για έναν άλλο αναστολέα διαύλου νατρίου θέσης I, διεξήχθηκαν μελέτες για την ταυτοποίηση των δοσολογιών της νεοσαξιτοξίνης («NeoSTX») και της βουπιβακαΐνης, μόνη ή σε συνδυασμό με την επινεφρίνη, για να παράσχει δύο έως τρεις ημέρες ανακούφισης από τον πόνο σε ανθρώπους. Οι συνδυασμοί βουπιβακαΐνης-NeoSTX παράγουν περισσότερο αξιόπιστο αποκλεισμό και μεγαλύτερη διάρκεια αποκλεισμού σε σύγκριση με τη NeoSTX μόνη. Ο συνδυασμός τριών οδών NeoSTX-βουπιβακαΐνης-επινεφρίνης παράγει περισσότερο παρατεταμένη τοπική αναισθησία σε σύγκριση με τον συνδυασμό δύο οδών NeoSTX-βουπιβακαΐνης. Η προσθήκη της επινεφρίνης σε αυτόν τον συνδυασμό NeoSTX-βουπιβακαΐνης παρατείνει δραματικά τη διάρκεια του πλήρους αποκλεισμού σε ένα μηχανικό ερέθισμα. Αυτά τα αποτελέσματα οδήγησαν στην ανάπτυξη σκευασμάτων δοσολογίας συγκεκριμένου συνδυασμού.
CY20191100416T 2013-03-15 2019-04-16 Σκευασματα συνδυασμου νεοσαξιτοξινης για παρατεταμενη τοπικη αναισθησια CY1121606T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789054P 2013-03-15 2013-03-15
PCT/US2014/030372 WO2014145580A1 (en) 2013-03-15 2014-03-17 Neosaxitoxin combination formulations for prolonged local anesthesia

Publications (1)

Publication Number Publication Date
CY1121606T1 true CY1121606T1 (el) 2020-05-29

Family

ID=50549480

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100416T CY1121606T1 (el) 2013-03-15 2019-04-16 Σκευασματα συνδυασμου νεοσαξιτοξινης για παρατεταμενη τοπικη αναισθησια

Country Status (26)

Country Link
US (4) US10314833B2 (el)
EP (2) EP2968225B1 (el)
JP (1) JP6313420B2 (el)
KR (4) KR20240042210A (el)
CN (1) CN105142625B (el)
AU (2) AU2014232881B2 (el)
CA (2) CA2906851C (el)
CL (1) CL2015002534A1 (el)
CY (1) CY1121606T1 (el)
DK (1) DK2968225T3 (el)
ES (1) ES2727292T3 (el)
HK (1) HK1218384A1 (el)
HR (1) HRP20190419T1 (el)
HU (1) HUE042711T2 (el)
IL (1) IL241346B (el)
LT (1) LT2968225T (el)
MX (1) MX2015012879A (el)
NZ (1) NZ710890A (el)
PE (1) PE20160011A1 (el)
PL (2) PL3492075T3 (el)
PT (1) PT2968225T (el)
RS (1) RS58750B1 (el)
RU (2) RU2015143665A (el)
SI (1) SI2968225T1 (el)
TR (1) TR201903411T4 (el)
WO (1) WO2014145580A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015012879A (es) * 2013-03-15 2016-06-24 Childrens Medical Center Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada.
US20170368176A1 (en) 2014-12-15 2017-12-28 The Children's Medical Center Corporation Non-toxic topical anesthetic ophthalmic compositions
US11344498B2 (en) 2015-10-08 2022-05-31 The Children's Medical Center Corporation Compositions and methods for on-demand high-efficiency triggerable anesthesia
US10117847B2 (en) 2015-12-04 2018-11-06 Ventis Pharma Extended duration local anesthetic formulation
US10791651B2 (en) 2016-05-31 2020-09-29 Carbice Corporation Carbon nanotube-based thermal interface materials and methods of making and using thereof
AU2018375002B2 (en) * 2017-12-01 2021-11-11 The Children's Medical Center Corporation Covalent anesthetic-polymer conjugates for prolonged local anesthesia
RU2701571C1 (ru) * 2019-02-13 2019-09-30 Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ профилактики болевого синдрома после вмешательств на коленном суставе
EP4087540A4 (en) * 2020-01-06 2024-01-10 Pacira Pharmaceuticals Inc TREATMENT OF PAIN ASSOCIATED WITH CESAREON SECTION USING SUSTAINED RELEASE LIPOSOMAL ANESTHETICS COMPOSITION
WO2021141959A1 (en) 2020-01-10 2021-07-15 Pacira Pharmaceuticals, Inc. Treatment of pain by administration of sustained-release liposomal anesthetic compositions
WO2021141963A1 (en) 2020-01-10 2021-07-15 Pacira Pharmaceuticals, Inc. Treatment of pain by subarachnoid administration of sustained-release liposomal anesthetic compositions
WO2022150708A1 (en) 2021-01-11 2022-07-14 Pacira Pharmaceuticals, Inc. Treatment of hip pain with sustained-release liposomal anesthetic compositions
US11931459B2 (en) 2021-03-19 2024-03-19 Pacira Pharmaceuticals, Inc. Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3004894A (en) 1959-04-07 1961-10-17 Upjohn Co Therapeutic composition comprising tetracycline and a dioxolane
US3328259A (en) 1964-01-08 1967-06-27 Parachem Corp Dressing for a wound containing a hemostatic agent and method of treating a wound
US3374144A (en) 1965-10-07 1968-03-19 Miles Lab Ophthalmic composition
SE391127B (sv) 1971-01-26 1977-02-07 Astra Pharma Prod Forfarande for framstellning av en lokalanetetiskt verksam injektionslosning med forlengd varaktighet av verkan
US3957996A (en) 1971-12-08 1976-05-18 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic compositions
US3966934A (en) 1971-12-08 1976-06-29 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4022899A (en) 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4029794A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic composition
US4029793A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4001413A (en) 1973-06-12 1977-01-04 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic composition employing saxitoxin
CA1165240A (en) 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4313958A (en) 1980-10-24 1982-02-02 The Procter & Gamble Company Method of producing analgesia
US4460602A (en) 1981-06-30 1984-07-17 The Procter & Gamble Company Urea derivatives
US4443473A (en) 1981-06-30 1984-04-17 The Procter & Gamble Company Carbamate derivatives
US4401663A (en) 1981-06-30 1983-08-30 The Procter & Gamble Company Novel sulfonamide derivatives
US4537776A (en) 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4544668A (en) 1983-07-14 1985-10-01 The Procter & Gamble Company Compounds and compositions useful for producing analgesia
US4544669A (en) 1983-07-14 1985-10-01 The Procter & Gamble Company Compounds and compositions useful for producing analgesia
US4493848A (en) 1983-07-14 1985-01-15 The Procter & Gamble Company Compositions and methods useful for producing analgesia
US4564633A (en) 1983-07-14 1986-01-14 The Procter & Gamble Company Compositions and methods useful for producing analgesia
US4605670A (en) 1984-02-01 1986-08-12 Nitto Electric Industrial Co., Ltd. Method for percutaneously administering metoclopramide
CA1274508A (en) 1984-05-31 1990-09-25 Imre Szilagyi Primycin components and process for the separation of the antibiotic complex
US4654323A (en) 1984-11-13 1987-03-31 Bar Ilan University Method and composition for the therapeutic and prophylactic treatment of trauma to the skin
US5013759A (en) 1985-06-10 1991-05-07 The Procter & Gamble Company Compounds and compositions having anti-inflammatory and analgesic activity
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US5006342A (en) 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US5045565A (en) 1987-03-09 1991-09-03 The Procter & Gamble Company Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain
US5099030A (en) 1987-03-09 1992-03-24 The Procter & Gamble Company Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain
US4820720A (en) 1987-08-24 1989-04-11 Alza Corporation Transdermal drug composition with dual permeation enhancers
US5871472A (en) 1987-11-17 1999-02-16 Brown University Research Foundation Planting devices for the focal release of neuroinhibitory compounds
US5134166A (en) 1988-12-02 1992-07-28 Genderm Corporation Method for treating nasal disorders and headaches
US4997853A (en) 1988-12-02 1991-03-05 Galenpharma, Inc. Method and compositions utilizing capsaicin as an external analgesic
US5008289A (en) 1988-12-02 1991-04-16 Galenpharma, Inc. Composition for treating nasal disorders and headaches
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
WO1993011798A1 (en) 1991-12-16 1993-06-24 Alza Corporation Improved formulations with hydrophobic permeation enhancers
US5618563A (en) 1992-09-10 1997-04-08 Children's Medical Center Corporation Biodegradable polymer matrices for sustained delivery of local anesthetic agents
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
AU1888195A (en) 1994-03-17 1995-10-03 Nanning Maple Leaf Pharmaceutical Co. Ltd. The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence
CN1156961A (zh) 1995-06-09 1997-08-13 欧罗赛铁克股份有限公司 产生长效局部麻醉的制剂和方法
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
WO1998043619A2 (en) 1997-04-02 1998-10-08 The Regents Of The University Of California Method of local anesthesia
AU7389098A (en) 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
US7016870B1 (en) 1997-12-02 2006-03-21 Financial Engines Identifying a recommended portfolio of financial products for an investor based upon financial products that are available to the investor
AU5286901A (en) 1999-10-22 2001-06-18 Transdermatech, Inc. Topical anesthetic formulation
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
CN1284536C (zh) 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
CN1236773C (zh) 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
JP2004521111A (ja) * 2001-01-25 2004-07-15 ユーロ−セルティーク，エス．エイ． 局所麻酔薬および使用法
CN1382443A (zh) 2001-04-25 2002-12-04 威克斯医疗仪器有限公司 钠离子通道阻断剂在制备用于局部神经麻醉或镇痛的药物中的应用
EA006739B1 (ru) * 2001-11-15 2006-04-28 Майкроу Элджи Корпорейшн Фармацевтические композиции, содержащие 3,4-пропинопергидропурины, и их применение для блокирования нейронной передачи
US20050202093A1 (en) 2002-12-02 2005-09-15 Kohane Daniel S. Prolonged suppression of electrical activity in excitable tissues
US20040172354A1 (en) 2003-02-13 2004-09-02 Charnley James Allen Calculator for illustrating investment performance for irregular time periods
WO2005079157A2 (en) 2004-02-19 2005-09-01 Dmitry Gorbatovsky Portfolio optimization
US20050214325A1 (en) 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
CN101123967A (zh) 2004-05-07 2008-02-13 菲特托克斯有限公司 藻毒素的经皮给药
CN100367966C (zh) 2004-09-28 2008-02-13 黄致强 河鲀毒素油相制剂的制备方法
WO2006091719A2 (en) 2005-02-23 2006-08-31 Sontra Medical Corporation Compositions and methods enhancing transdermal delivery of drugs and biologics
ES2402789T3 (es) 2006-11-20 2013-05-08 President And Fellows Of Harvard College Métodos, composicones y kits para tratar dolor y prurito
US8609733B2 (en) 2008-05-19 2013-12-17 Massachusetts Institute Of Technology Sensory-specific local anesthesia and prolonged duration local anesthesia
WO2009143174A2 (en) 2008-05-19 2009-11-26 Children's Medical Center Corporation Chemical permeation enhancers enhance nerve blockade by toxins
WO2010041255A2 (en) 2008-10-07 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Liposomal systems comprising sphingomyelin
CL2009000723A1 (es) 2009-03-24 2009-06-19 Proteus Sa Metodo de purificacion industrial de ficotoxinas biologicamente activas que comprende proporcionar una cantidad adecuada de una fuente de ficotoxinas como por ejemplo el cultivo de un clon de cianobacterias.
CL2009000722A1 (es) 2009-03-24 2009-06-19 Proteus Sa Metodo de obtención y producción masiva de una especie de cianobacteria aislada productora de ficotoxinas paralizantes, utilizando un medio de cultivo mla suplementado con arginina, metionina y ácido alantoico.
US20120034296A1 (en) 2009-04-08 2012-02-09 Massachusetts Institute Of Technology Prolonged duration local anesthesia with minimal toxicity
WO2010129864A2 (en) 2009-05-07 2010-11-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for studying, imaging, and treating pain
WO2011098539A1 (en) * 2010-02-10 2011-08-18 Phytotox Limited Treatment of loss of sense of touch with saxitoxin derivatives
MX2015012879A (es) * 2013-03-15 2016-06-24 Childrens Medical Center Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada.

Also Published As

Publication number Publication date
IL241346B (en) 2018-07-31
KR20220132666A (ko) 2022-09-30
AU2014232881B2 (en) 2017-04-27
US20190247377A1 (en) 2019-08-15
US20140288103A1 (en) 2014-09-25
IL241346A0 (en) 2015-11-30
NZ710890A (en) 2016-11-25
CA2906851A1 (en) 2014-09-18
US10314833B2 (en) 2019-06-11
EP3492075B1 (en) 2023-12-13
PL3492075T3 (pl) 2024-04-22
CA3018668C (en) 2021-04-13
KR20240042210A (ko) 2024-04-01
US10881647B2 (en) 2021-01-05
CN105142625B (zh) 2019-09-06
US8975268B2 (en) 2015-03-10
US20140329841A1 (en) 2014-11-06
RU2673081C1 (ru) 2018-11-22
CA2906851C (en) 2019-05-07
MX2015012879A (es) 2016-06-24
AU2017202343B2 (en) 2019-02-07
AU2014232881A1 (en) 2015-08-27
JP6313420B2 (ja) 2018-04-18
HK1218384A1 (zh) 2017-02-17
HUE042711T2 (hu) 2019-07-29
AU2017202343A1 (en) 2017-04-27
CA3018668A1 (en) 2014-09-18
CN105142625A (zh) 2015-12-09
HRP20190419T1 (hr) 2019-05-03
SI2968225T1 (sl) 2019-05-31
PE20160011A1 (es) 2016-02-10
LT2968225T (lt) 2019-04-25
US8975281B2 (en) 2015-03-10
RU2015143665A (ru) 2017-04-27
RS58750B1 (sr) 2019-06-28
JP2016514704A (ja) 2016-05-23
DK2968225T3 (da) 2019-05-27
TR201903411T4 (tr) 2019-04-22
KR20210062693A (ko) 2021-05-31
EP2968225A1 (en) 2016-01-20
EP3492075A1 (en) 2019-06-05
KR20150131330A (ko) 2015-11-24
US20140329861A1 (en) 2014-11-06
PT2968225T (pt) 2019-04-02
CL2015002534A1 (es) 2016-09-16
ES2727292T3 (es) 2019-10-15
BR112015021380A2 (pt) 2018-05-08
PL2968225T3 (pl) 2019-08-30
EP2968225B1 (en) 2019-02-20
WO2014145580A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
CY1121606T1 (el) Σκευασματα συνδυασμου νεοσαξιτοξινης για παρατεταμενη τοπικη αναισθησια
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CY1122909T1 (el) Μεθοδοι αντιμετωπισης της ηωσινοφιλικης οισοφαγιτιδας με χορηγηση αναστολεα του ιl-4r
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
CY1120950T1 (el) Θεραπεια ινωσης
CY1121735T1 (el) 7-benzyλ-10-(2-meθyλobenzyλ)-2,6,7,8,9,10-eξaϋδpoϊmiδazo[1,2-α]πυριδο[4,3-d]πυριμιδιν-5(3η)-ονη για χρηση στην αγωγη του καρκινου
CY1123914T1 (el) Αντιμετωπιση των αυξημενων επιπεδων ηωσινοφιλων και/ή βασεοφιλων
CY1119676T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια του καρκινου
CR20160170A (es) Moduladores del factor del complemento b
CY1119618T1 (el) Ενωσεις και συνθεσεις ως ρυθμιστικα μορια της tlr δραστηριοτητας
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CL2018001996A1 (es) Composiciones y métodos para modular la expresión del factor b del complemento (divisional de solicitud 2764-16)
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
CL2020003174S1 (es) Dispositivo para administración de dosis.
CY1121628T1 (el) 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης
CY1122113T1 (el) Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
CY1121514T1 (el) Δευτεριωμενα 1-πiπεραζινo-3-φαινυλικα ινδανια για τη θεραπευτικη αντιμετωπιση της σχιζοφρενιας
CY1122387T1 (el) Διπλης χρησης δισκια στοματικης φαρμακευτικης συνθεσης θειικων αλατων και μεθοδοι χρησης αυτων
CY1120075T1 (el) Καρβορανυλο-πορφυρινες για χρηση στη θεραπεια του καρκινου
EA201690874A1 (ru) Препятствующие злоупотреблению гранулированные лекарственные формы с немедленным высвобождением
UY35823A (es) Profármacos de antagonista de nmda
CY1122348T1 (el) Μεθοδος για την θεραπευτικη αντιμετωπιση της ηπατικης εγκεφαλοπαθειας